Medscape1d
Topical Ruxolitinib Improves Itch, Blistering in Prurigo Nodularis in Study
Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
Healio1d
Filgotinib well-tolerated, efficacious for up to 8 years in rheumatoid arthritis
Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...
HealthDay on MSN5d
AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata
For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses o ...
Treating chronic inflammatory diseases with JAK inhibitors
Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...
The American Journal of Managed Care9d
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...
MPR4d
Ivarmacitinib 4mg, 8mg Efficacious for Adults With Severe Alopecia Areata
HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...